Vertical: CNMBase Year: 2025
Market Size (2025)
$1.47B
Projected (2032)
$1.92B
CAGR (2022–2032)
4.6%
Key Players
11+
Market Overview
The Global Bio-Based Surfactants Market was valued at USD 1,469.83 Million in 2025 and is projected to reach USD 1,924.24 Million by 2032, expanding at a CAGR of 3.81% over the forecast period 2026–2032. The market grew from USD 1,230.73 Million in 2022, and is expected to add USD 454.40 Million in absolute value between 2025 and 2032. Bio-based surfactants in the scope of this study are surface-active molecules produced by microbial fermentation, principally glycolipids such as sophorolipids and rhamnolipids, and lipopeptides such as surfactin. They are gaining adoption because they deliver cleaning, foaming, wetting and emulsifying performance with ready biodegradability, low toxicity and a renewable carbon footprint, at a time when consumer goods companies are committed to removing fossil carbon from their formulations and regulators are tightening requirements on detergent and cosmetic ingredients.
Key Findings
Product Type: Glycolipids (Sophorolipids & Rhamnolipids) is the largest and fastest-growing product type, valued at USD 955.39 Million in 2025 (65.00% share) and growing at a CAGR of 4.42% to reach USD 1,303.55 Million by 2032.
Application: Household Detergents is the largest application at USD 514.44 Million in 2025 (35.00% share), while Personal Care is the fastest-growing at a CAGR of 5.33%, rising to USD 534.13 Million by 2032.
Region: Europe is the leading region with USD 558.54 Million in 2025 (38.00% share). Middle East & Africa is the fastest-growing region at a CAGR of 5.60%, and Asia Pacific records the largest absolute increase, adding USD 182.41 Million between 2025 and 2032.
Country: The U.S. is the leading country market, valued at USD 252.22 Million in 2025. The UAE is the fastest-growing country at a CAGR of 6.37%, followed by India at 6.10%.
Segmentation Summary
By product type, glycolipids dominate because sophorolipids and rhamnolipids are the only biosurfactant classes produced at industrial scale for mass-market consumer products; their share is projected to rise steadily through 2032. Lipopeptides & Others, valued at USD 514.44 Million in 2025, serve specialist niches in premium cosmetics, crop protection and oilfield applications and grow at a CAGR of 2.61%.
By application, Household Detergents remains the largest outlet throughout the forecast period, but consumer-facing Personal Care (5.33% CAGR) and Agriculture (5.03% CAGR) grow fastest. Oilfield & Others, valued at USD 367.46 Million in 2025, grows at a CAGR of 2.57% and gradually loses share. Regionally, Europe and Asia Pacific together accounted for more than seventy per cent of 2025 value, with Asia Pacific closing the gap with Europe by 2032.
Competitive Landscape Summary
The market is moderately consolidated at the top and fragmented in the long tail. Evonik, which operates the first industrial-scale rhamnolipid plant, and the long-established Japanese producers Saraya and Kaneka lead the market. Chemical majors BASF and Sasol participate mainly through equity stakes and partnerships with fermentation specialists, while Locus Fermentation Solutions and Holiferm are scaling rapidly, and Stepan, Allied Carbon Solutions, AGAE Technologies and Jeneil Biotech compete in specific molecules, applications and regions. Competition centres on production cost, capacity, regulatory registrations and partnerships with brand owners. Since 2022, the industry has seen the commissioning of the first industrial-scale rhamnolipid plant, new sophorolipid capacity in the United Kingdom, multiple distribution and offtake agreements between specialists and chemical majors, and significant venture and debt financing for capacity expansion.
Challenges and Opportunities
The principal challenge is cost. Biosurfactants typically remain several times more expensive per kilogram than petrochemical and conventional oleochemical surfactants, because fermentation titres, productivity and downstream purification costs have not yet reached commodity economics. Limited installed capacity, the concentration of supply among a small number of producers and the time needed for brand owners to qualify new ingredients further constrain adoption. Feedstock price volatility for sugars and vegetable oils adds to cost uncertainty.
Opportunities are substantial. New industrial-scale plants are lowering unit costs, and the use of waste and by-product feedstocks can improve both economics and sustainability credentials. Personal care brands are willing to pay a premium for mild, natural-origin ingredients, agriculture offers fast-growing demand for adjuvants and biological actives, and emerging markets in Asia Pacific, Latin America and the Middle East & Africa provide room for capacity investment close to growing demand.
Future Outlook
The market is expected to move from early commercialisation towards broader industrial adoption over 2026–2032. Annual market value is projected to rise from USD 1,537.61 Million in 2026 to USD 1,924.24 Million in 2032. Growth will be led by glycolipids, personal care and agriculture, and by Asia Pacific, the Middle East & Africa and Latin America. Partnerships between biotechnology specialists, chemical majors and consumer goods companies, together with continued capacity expansion, will be decisive in narrowing the cost gap with conventional surfactants and determining which suppliers capture the next phase of growth.
The Bio-Based Surfactants Market market is projected to grow at a CAGR of 4.6% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Bio-based surfactants, in the scope of this study, are amphiphilic surface-active compounds synthesised by microorganisms, including yeasts and bacteria, through fermentation of renewable carbon sources such as sugars, starch hydrolysates, glycerol and vegetable oils. Their molecules consist of a hydrophilic head group, which may be a carbohydrate, a peptide or an amino acid, linked to a hydrophobic fatty acid or hydroxy fatty acid tail. They reduce surface and interfacial tension and act as detergents, wetting agents, foaming agents, emulsifiers and dispersants.
The market includes glycolipids, chiefly sophorolipids and rhamnolipids, and lipopeptides, chiefly surfactin, iturin and fengycin, together with other microbially derived surfactants such as mannosylerythritol lipids, trehalolipids, cellobiose lipids and polymeric biosurfactants. It covers products supplied as purified actives, concentrates or formulated surfactant blends for use in household detergents, personal care, agriculture, and oilfield and other industrial applications.
The market excludes surfactants that are manufactured by chemical synthesis from bio-based raw materials, such as alkyl polyglucosides, sugar esters, methyl ester sulfonates, fatty alcohol sulfates and ethoxylates, and amino acid surfactants made by chemical condensation, even where their carbon content is fully renewable. Petrochemical surfactants, microbial cultures sold as live biological products, and finished consumer products are also excluded; only the value of the biosurfactant ingredient is counted.
Scope of the Study
The study provides historic data for 2022, 2023 and 2024, uses 2025 as the base year, and presents forecasts for 2026 to 2032. Compound annual growth rates are presented for 2026–2032, and all values are expressed in USD Million. The market is analysed by the following segmentations:
By Product Type: Glycolipids (Sophorolipids & Rhamnolipids); Lipopeptides & Others.
By Application: Household Detergents; Personal Care; Agriculture; Oilfield & Others.
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA).
For each region and country, the market is further analysed by product type and by application. The study also profiles the leading companies active in the market and examines the drivers, restraints, opportunities, regulations and competitive forces shaping it.
Research Objectives
To estimate the size of the global bio-based surfactants market for 2022–2025 and forecast it for 2026–2032 in USD Million.
To quantify the market by product type, distinguishing glycolipids (sophorolipids and rhamnolipids) from lipopeptides and other biosurfactants.
To analyse demand across household detergents, personal care, agriculture, and oilfield and other applications, and identify the applications with the highest growth potential.
To assess market size and growth across five regions and twenty country-level markets, including region-by-segment and country-by-segment splits.
To evaluate the drivers, restraints, opportunities, trends and challenges affecting the commercial adoption of biosurfactants as substitutes for petrochemical surfactants.
To examine the regulatory and certification frameworks for detergent, cosmetic, agricultural and bio-based products that influence demand in major regions.
To analyse the value chain and competitive intensity using Porter's Five Forces and PESTEL frameworks.
To profile leading producers and track their products, capacity investments, partnerships and other strategic developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study was developed through a structured, multi-stage research process. It began with the definition of the market scope and segmentation, followed by extensive secondary research to build an understanding of the biosurfactant value chain, producers, technologies, applications and regulations. Primary research with participants across the supply and demand sides was then used to validate and refine assumptions. Market size was estimated using both top-down and bottom-up approaches, which were reconciled through data triangulation, and a forecasting model was built to project the market to 2032. The final dataset was reviewed for internal consistency across segments, regions and countries.
Secondary Research
Secondary research drew on sources specific to the surfactant, industrial biotechnology and consumer goods industries:
Industry associations: organisations such as the European Committee of Organic Surfactants and their Intermediates (CESIO), the American Cleaning Institute, A.I.S.E. (International Association for Soaps, Detergents and Maintenance Products), Cosmetics Europe, the Biotechnology Innovation Organization and the Biobased Industries Consortium.
Government and regulatory bodies: the European Commission, the European Chemicals Agency, the U.S. Department of Agriculture BioPreferred Program, the U.S. Environmental Protection Agency, national chemical regulators and statistical agencies, and trade data repositories.
Company filings: annual reports, sustainability reports, investor presentations, press releases and product literature from biosurfactant producers, chemical companies and consumer goods brand owners.
Trade journals and scientific literature: surfactant, cosmetics, agrochemical and biotechnology publications, peer-reviewed research on fermentation yields and production costs, and patent databases.
Paid databases: company financial databases, trade statistics services and industry market intelligence platforms.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions with industry participants to validate secondary findings, fill information gaps and obtain forward-looking insights. On the supply side, respondents included executives, business development managers, R&D and production specialists at biosurfactant producers, specialty chemical companies, fermentation contract manufacturers and ingredient distributors. On the demand side, respondents included formulation scientists, procurement managers and sustainability leads at household and personal care brand owners, agrochemical and biologicals formulators, and oilfield service and remediation companies. Independent experts from academia and research institutes were also consulted.
The objectives of primary research were to verify production capacities and pricing, understand the adoption drivers and barriers in each application, assess the competitive positioning of suppliers, and validate segment, regional and country splits and growth expectations.
Market Size Estimation
In the top-down approach, the total surfactant market and the specialty and bio-based surfactant sub-markets were used as reference points, and penetration rates of microbially produced biosurfactants were applied by application and region based on secondary data and expert input. In the bottom-up approach, the revenues of biosurfactant producers were estimated from company disclosures, production capacities, utilisation rates and average selling prices, and aggregated by product type and region; demand-side estimates of consumption by application and country were built in parallel.
The results of the two approaches were compared and reconciled through data triangulation, in which supply-side, demand-side and expert-derived estimates were cross-checked. Where differences arose, the underlying assumptions were reviewed and adjusted until the estimates converged within an acceptable range.
Forecasting Methodology
The forecast was built using a factor-based model that combines historic trends with forward-looking assessments of the variables that influence demand. Factors considered include new production capacity and its timing, expected changes in production costs and selling prices, brand owner reformulation commitments, regulatory changes affecting detergent, cosmetic and agricultural ingredients, growth of the end-use industries, macroeconomic conditions, and feedstock and energy price trends. Growth rates were developed for each segment, region and country and reconciled so that the sum of segments equals the total for each region and the sum of regions equals the global market in every year.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024.
Base year: 2025.
Forecast period: 2026–2032, with CAGR calculated for 2026–2032.
Currency and unit: USD Million at current prices.
Assumptions and Limitations
Market values are measured at the level of the biosurfactant ingredient sold by the producer and do not include the value of finished consumer or industrial products.
Exchange rates are assumed to remain broadly stable over the forecast period, and values are not adjusted for inflation.
Announced capacity additions are assumed to come on stream broadly as scheduled; material delays would affect supply growth.
No major disruption to global trade, feedstock supply or regulatory frameworks beyond those already announced is assumed.
Many biosurfactant producers are privately held and do not disclose segment revenues, so supplier-level estimates rely on triangulated assumptions and carry a higher degree of uncertainty.
"Rest of" country groupings aggregate several markets and are analysed as single units.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Bio-Based Surfactants Market is at an early stage of industrialisation and has a moderately consolidated structure at the top, with a fragmented tail of smaller specialists. A limited number of chemical companies and established producers operate industrial-scale fermentation capacity or control large-volume supply through partnerships, while a wider group of biotechnology companies, many of them venture-backed, compete with proprietary strains, process technologies and application-specific grades.
Competition is driven less by price than by the ability to deliver consistent quality at scale, reduce production costs, secure regulatory registrations such as REACH and TSCA, and win long-term supply agreements with brand owners. Partnerships are a defining feature: chemical majors provide scale-up, regulatory and commercial reach, while specialists provide strains and processes. Consumer goods companies increasingly co-develop biosurfactant products with suppliers and, in some cases, commit to offtake volumes that underwrite new plants.
Key Player Positioning
Leaders are companies with industrial-scale production, broad application coverage and strong brand owner relationships: Evonik, Saraya, Kaneka. Challengers are companies scaling quickly through new capacity, partnerships or broad distribution: BASF, Sasol, Locus FS, Holiferm. Niche players focus on particular molecules, applications or regions: Stepan, Allied Carbon Solutions, AGAE Technologies, Jeneil Biotech. Positioning is qualitative and reflects scale of biosurfactant operations, portfolio breadth, geographic reach and partnerships.
Evonik Industries AG
Overview: Evonik is a global specialty chemicals company with production in 27 countries. Biosurfactants form part of its Custom Solutions activities and its portfolio of next-generation sustainable solutions. Evonik operates the first industrial-scale rhamnolipid plant and supplies glycolipid biosurfactants to both home care and personal care customers.
Revenue: Sales of EUR 14.1 billion in fiscal year 2025.
Relevant products: RHEANCE One glycolipid for personal care cleansing, SOPHANCE LA-A sophorolipid for facial cleansers, mild shampoos and oral care, and the REWOFERM range of biosurfactants for household cleaners and detergents. Its rhamnolipids are produced by fermentation of corn-based sugar without tropical oils.
Key developments: In January 2022, Evonik announced a three-digit million-euro investment in the world's first industrial-scale rhamnolipid plant at Slovenská Ľupča, Slovakia, strengthening its partnership with Unilever, which uses Evonik rhamnolipids in hand dishwashing liquids. Construction began in June 2022, the first product was manufactured at the site in January 2024, and the plant was inaugurated in May 2024. In June 2026, Evonik formed a partnership with the University of Guanajuato, Mexico, to develop lower-toxicity mining chemicals using its rhamnolipid platform.
Strategy: Evonik aims to lead the industrial production of biosurfactants by combining large-scale fermentation with exclusive partnerships with brand owners, serving home care and personal care and extending its rhamnolipid platform into industrial applications such as mining.
Saraya Co., Ltd.
Overview: Saraya is a privately held Japanese health and hygiene company founded in 1952, with overseas subsidiaries and factories across Asia, Europe, the Americas and Africa. It began sophorolipid research in 1997, achieved stable production in 2001, and is regarded as one of the first companies to commercialise a natural biosurfactant.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: SOFORO sophorolipid produced by yeast fermentation of sugar and RSPO-certified vegetable oil, used in its SOFORON dishwasher detergent, Happy Elephant eco-detergent range and hair care, and in medical-instrument cleaning and other specialty applications.
Key developments: In May 2025, Saraya showcased SOFORO at Expo 2025 Osaka. In September 2025, it launched Happy Elephant Foam Multi Cleaner containing SOFORO nationwide in Japan, and in March 2026 it introduced a paper-carton refill of its Happy Elephant liquid laundry detergent, which contains SOFORO, reducing plastic use by more than 90%.
Strategy: Saraya is vertically integrated, using its sophorolipid mainly in its own branded hygiene and eco-detergent products, and is developing higher-value uses such as high-purity cosmetic grades, food grades and medical applications.
Kaneka Corporation
Overview: Kaneka is a diversified Japanese chemical company founded in 1949, organised into Material, Quality of Life, Health Care and Nutrition solutions units. Its surfactin business, housed in the Quality of Life unit, is one of the leading commercial sources of lipopeptide biosurfactant.
Revenue: Consolidated net sales of JPY 811.6 billion for the fiscal year ended 31 March 2026.
Relevant products: KANEKA Surfactin (INCI: Sodium Surfactin), a cyclic lipopeptide produced by fermentation of Bacillus subtilis that is effective at very low concentrations, and KANEKA Premix grades, with COSMOS, ECOCERT and NATRUE certifications.
Key developments: Kaneka continues to market surfactin globally through distributors, including Brenntag in the United States and its European subsidiary in Belgium. In February 2022, it committed around JPY 15 billion to expand fermentation-based PHBH biopolymer capacity at its Takasago site, strengthening its industrial fermentation base, and its management plan sets out JPY 300 billion of investment for fiscal years 2025–2027 with a shift towards leading-edge businesses.
Strategy: Kaneka positions surfactin as a high-value, low-dosage cosmetic ingredient and leverages its fermentation expertise across biopolymers, nutrition and biosurfactants under its life-science-oriented growth strategy.
BASF SE
Overview: BASF is the world's largest chemical producer. Its biosurfactant activities sit within the personal and home care business of Nutrition & Care, one of the core businesses under its Winning Ways strategy announced in 2024. BASF is also a major producer of chemically synthesised bio-based surfactants such as alkyl polyglucosides, which are outside the scope of this study.
Revenue: Sales of EUR 59.7 billion in fiscal year 2025.
Relevant products: Sophorolipid biosurfactant for personal care developed with Allied Carbon Solutions, including the BioToLife ingredient launched in Asia, and development of fermentation-derived glycolipids for home care, industrial and personal care uses.
Key developments: BASF became the largest shareholder of Allied Carbon Solutions through a strategic alliance announced in 2021, and in October 2024 its partner raised JPY 550 million to expand sophorolipid production and sales in Asia, the Middle East and Europe. In November 2025, BASF expanded its bio-based surfactant production capacity at Bangpakong, Thailand.
Strategy: BASF participates in biosurfactants through equity stakes and partnerships rather than its own fermentation plants, combining partner technologies with its global personal and home care customer base and broad bio-based surfactant portfolio.
Stepan Company
Overview: Stepan is a U.S. producer of surfactants, polymers and specialty products founded in 1932. It entered biosurfactants through the acquisition of the NatSurFact rhamnolipid business from Logos Technologies in 2020 and of a fermentation plant at Lake Providence, Louisiana, in 2021.
Revenue: Net sales of USD 2,332.1 million in fiscal year 2025.
Relevant products: NatSurFact fermentation-derived rhamnolipids targeted at agriculture, oilfield, personal care and industrial cleaning applications.
Key developments: In November 2022, Stepan identified biosurfactants as one of its next-generation growth platforms. In December 2025, it agreed to sell and then completed the sale of its Lake Providence, Louisiana, manufacturing assets, the site it had acquired as a potential biosurfactant fermentation facility, as part of a manufacturing footprint optimisation programme.
Strategy: Stepan is concentrating its manufacturing footprint on core growth areas within its surfactant business, and its biosurfactant activities are positioned as a specialty platform alongside its large conventional and bio-based surfactant portfolio.
Sasol Limited
Overview: Sasol is an integrated energy and chemicals company headquartered in South Africa, with chemicals operations in Africa, the Americas and Eurasia. Through its Chemicals business, Sasol is one of the world's largest producers of surfactants and surfactant intermediates, and it has entered biosurfactants through a strategic partnership with Holiferm.
Revenue: Turnover of ZAR 272,118 million for the financial year ended 30 June 2026.
Relevant products: CARINEX SL sophorolipids for personal care and LIVINEX SL sophorolipids for home care, both produced using Holiferm's fermentation technology; collaborative development of rhamnolipids and mannosylerythritol lipids.
Key developments: In March 2022, Sasol entered a partnership with Holiferm under which it takes the majority of the output of Holiferm's sophorolipid plant and supports R&D. In January 2023, the collaboration was extended to rhamnolipids and mannosylerythritol lipids. In October 2023, Sasol launched the CARINEX SL and LIVINEX SL biosurfactant ranges.
Strategy: Sasol combines its global surfactant customer base, application know-how and distribution network with a technology partner's fermentation platform, allowing it to offer biosurfactants alongside its conventional and bio-based surfactant portfolio without building its own fermentation capacity.
Locus Fermentation Solutions
Overview: Locus Fermentation Solutions is a U.S. fermentation biomanufacturer of glycolipid biosurfactants, chiefly sophorolipids, and other biologicals. It operates through divisions serving consumer ingredients (Locus Ingredients, formerly Locus Performance Ingredients), oil and gas (Locus Bio-Energy), agriculture and mining.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: Amphi range of sophorolipids (linear and lactonic grades), Ferma range of glycolipids for personal care, and SUSTAIN biosurfactant-based products for oilfield applications.
Key developments: In February 2022, Dow signed an exclusive agreement to market Locus sophorolipids to the global personal care industry. In September 2022, the company obtained REACH registrations for its sophorolipid range and entered the EU market. In April 2023, it agreed an exclusive collaboration with Veolia Water Technologies & Solutions on water treatment additives, and in 2023 it secured a USD 117 million IP-backed loan to expand manufacturing. In October 2024, its full glycolipid line was listed on the U.S. TSCA Inventory. In December 2025, it raised a USD 20 million convertible note, and in September 2026 it acquired a facility in Midland, Texas, tripling its Permian blending capacity.
Strategy: Locus uses a single sophorolipid fermentation platform to serve several sectors, partnering with Dow in personal care while prioritising industrial markets such as oil and gas, mining and agriculture. It supports this with a large patent estate, domestic manufacturing and regulatory listings.
Holiferm Ltd
Overview: Holiferm is a University of Manchester spin-out founded in 2018 that produces sophorolipids by fermentation using an integrated gravity-separation process. It operates R&D facilities in Manchester and a commercial plant at Wallasey, Wirral, and is developing rhamnolipids and mannosylerythritol lipids.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: HoliSurf HF (high foam) and HoliSurf LF (low foam) sophorolipids, COSMOS-approved, for personal care and cleaning; technology licensed for Sasol's CARINEX SL and LIVINEX SL ranges.
Key developments: In March 2022, Holiferm formed a strategic partnership with Sasol. In February 2023, it opened its first commercial biosurfactant plant at Ocean Park, Wallasey, with initial capacity of about 1,100 tonnes per year. In December 2023, it raised GBP 18.5 million to expand capacity, with a plan to reach 3,500 tonnes per year and subsequently 15,000 tonnes per year. In May 2025, Creatreats became its distributor in Spain and Portugal, and in September 2026 Holiferm announced a strategic combination with cleaning products manufacturer Organica.
Strategy: Holiferm aims to be a low-cost, low-carbon glycolipid producer, using its energy-efficient separation technology and selling through an offtake partnership with Sasol and regional distributors, while moving closer to finished formulations.
Allied Carbon Solutions Co., Ltd.
Overview: Allied Carbon Solutions, founded in 2006, produces sophorolipids by yeast fermentation of plant oils and sugars using process technology developed with Japan's National Institute of Advanced Industrial Science and Technology. BASF is its largest shareholder following an equity investment in 2021.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: ACS-Sophor sophorolipid emulsifier for animal feed and aquaculture, Sophomore sophorolipids for home care, sophorolipid-based agricultural biostimulants, and supply of sophorolipid for BASF's personal care biosurfactant offering.
Key developments: In October 2024, the company raised JPY 550 million in a Series C round to expand production in Japan and overseas and build sales channels in Asia, the Middle East and Europe. In June 2025, it was selected by UNIDO for a feasibility study on producing sophorolipids from Ukrainian sunflower oil. In March 2026, it launched a biostimulant for heat and drought stress.
Strategy: The company focuses on agriculture, animal nutrition and home care, while partnering with BASF in personal care, and is expanding production and sales outside Japan.
AGAE Technologies LLC
Overview: AGAE Technologies is a rhamnolipid specialist founded in Oregon that supplies high-purity research-grade rhamnolipids, distributed under the Sigma-Aldrich brand, as well as commercial grades and custom rhamnolipid formulations.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: R90 and R95 rhamnolipids, R95MD mono-rhamnolipid-dominant grade, and commercial rhamnolipid grades for home care, personal care, enhanced oil recovery and remediation.
Key developments: In August 2022, AGAE announced dedicated rhamnolipid fermentation and purification pilot plants in North America, and in September 2022 it reported substantially higher yields and lower production costs. In February 2025, it announced industrial production of rhamnolipids from a full-scale manufacturing plant in Asia with capacity of more than 1,000 tonnes per year.
Threat of New Entrants: Medium
Building industrial-scale fermentation and purification capacity requires significant capital and specialised process know-how, and strain and process patents protect incumbents.
Venture capital, public grants and partnerships with chemical companies have enabled several start-ups to reach commercial production, lowering the barrier for well-funded entrants.
Contract fermentation capacity offers an asset-light entry route, though it limits cost control.
Bargaining Power of Suppliers: Low
Primary feedstocks are traded agricultural commodities available from many suppliers in all major regions.
Producers can switch between sugar, oil and glycerol sources within the tolerance of their fermentation processes.
Specialised equipment and contract manufacturing capacity are more concentrated, giving these suppliers moderate leverage.
Bargaining Power of Buyers: High
Large multinational home and personal care companies account for a substantial share of volume and negotiate long-term contracts on price and supply terms.
Buyers can choose among biosurfactants, chemically synthesised bio-based surfactants and conventional surfactants, giving them alternatives.
Smaller cosmetic and specialty formulators have less leverage, which moderates buyer power in premium segments.
Threat of Substitutes: High
Petrochemical surfactants are mature, low-cost and available in very large volumes.
Alkyl polyglucosides, sugar esters, amino acid surfactants and other bio-based alternatives meet many renewable-carbon objectives at lower cost.
Distinctive mildness, biodegradability and biological activity of biosurfactants partly offset the threat in premium and specialised uses.
Competitive Rivalry: Medium
The market has a limited number of established suppliers with distinct technology platforms and application focuses.
Competition centres on cost reduction, capacity, product performance, regulatory support and brand owner partnerships.
Rapid market growth reduces direct price competition, although rivalry is expected to intensify as new capacity comes on stream.
Threat of New Entrants: Medium; High capital and know-how barriers to industrial scale, offset by strong venture funding and partnerships that support new entrants.
Bargaining Power of Suppliers: Low; Feedstocks such as sugars, glycerol and vegetable oils are widely available commodities from many suppliers.
Bargaining Power of Buyers: High; A small number of large brand owners account for much of the demand and can compare biosurfactants with cheaper alternatives.
Threat of Substitutes: High; Petrochemical and chemically synthesised bio-based surfactants offer comparable function at lower cost and larger scale.
Competitive Rivalry: Medium; A limited number of established producers, with competition based on cost, capacity, performance and partnerships rather than price alone.
Market estimates by geography (2032)
InsightEurope leads with $695.38M by 2032, while Middle East & Africa is projected to grow fastest at a 6.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $274.45M | $350.52M | $411.21M | 4.1% | 21% |
| Europe | $478.75M | $601.57M | $695.38M | 3.8% | 36% |
| Asia Pacific | $392.85M | $538.18M | $667.46M | 5.4% | 35% |
| Latin America | $49.60M | $66.18M | $85.05M | 5.5% | 4% |
| Middle East & Africa | $35.08M | $49.96M | $65.14M | 6.4% | 3% |
| Total | $1.23B | $1.61B | $1.92B | 4.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.92B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Glycolipids (Sophorolipids & Rhamnolipids) | $1.30B | 5.3% | 68% |
| Lipopeptides & Others | $620.68M | 3.2% | 32% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Bio-Based Surfactants Market covering market dynamics, competitive landscape, and strategic outlook.
The Bio-Based Surfactants Market market is projected to reach $1.92B by 2032, growing at 4.6% CAGR. The Glycolipids (Sophorolipids & Rhamnolipids) segment holds the largest share.
The Global Bio-Based Surfactants Market is shaped by the interplay between strong sustainability-driven demand and the cost and scale constraints of fermentation-based production. This chapter examines the macro and micro factors influencing growth, followed by the main drivers, restraints, opportunities, trends and challenges. The market is projected to grow from USD 1,469.83 Million in 2025 to USD 1,924.24 Million in 2032, a CAGR of 3.81% over 2026–2032.
Brand Owner Commitments to Replace Fossil Carbon in Cleaning Products
The most important demand driver is the commitment by global home and personal care companies to move their formulations away from fossil-derived carbon. Surfactants are the largest ingredient group in most cleaning products by carbon content, so they are central to these targets. Unilever's Clean Future programme, announced in September 2020, set a goal of replacing fossil-derived carbon in its cleaning and laundry formulations with renewable or recycled carbon by 2030, backed by a EUR 1 billion fund for biotechnology, carbon capture and low-carbon chemistry. Unilever and Evonik first brought a rhamnolipid into a mass-market dishwashing liquid, Quix in Chile, in 2019, and Evonik opened the first industrial-scale rhamnolipid plant at Slovenská Ľupča, Slovakia, in May 2024. Other brand owners have introduced sophorolipid- and rhamnolipid-based products in eco and concentrated ranges. These commitments translate into multi-year supply agreements that give producers the volume visibility required to justify investment in fermentation capacity. Because biosurfactants can be used as high-performance co-surfactants at modest inclusion levels, they also allow brand owners to raise renewable carbon content and improve environmental profiles without a full reformulation, accelerating adoption in Household Detergents, which was valued at USD 514.44 Million in 2025.
Tightening Regulation and Eco-Certification of Detergent and Cosmetic Ingredients
Regulatory frameworks increasingly favour ingredients that are readily biodegradable, of low aquatic toxicity and derived from renewable resources. In the European Union, the Detergents Regulation requires surfactants in detergents to be fully biodegradable, and its replacement, Regulation (EU) 2026/405 on detergents and surfactants, adopted in 2026 and applicable from September 2029, revises the biodegradability criteria further. The REACH Regulation imposes registration and hazard assessment obligations, and the EU Ecolabel criteria for detergents set stringent limits on aquatic toxicity and non-biodegradable organics. The European Commission's Strategic Framework for a Competitive and Sustainable EU Bioeconomy, adopted in November 2025, and the Green Deal support the substitution of fossil-based chemicals. In the United States, the USDA BioPreferred Program requires federal procurement to prioritise biobased products and certifies products for biobased content, while the EPA Safer Choice programme lists ingredients that meet safer-chemistry criteria. These frameworks raise the cost of compliance for some conventional surfactants and provide marketing advantages to products with certified bio-based and eco-label claims. Biosurfactants, which are inherently biodegradable and fully bio-based, are well positioned to benefit from this regulatory direction across all applications.
Clean Beauty and Demand for Mild Personal Care Ingredients
Personal Care is the fastest-growing application, expanding at a CAGR of 5.33% over 2026–2032. Consumers are increasingly seeking sulphate-free, gentle and natural-origin cleansing products, and beauty brands are responding with formulations that carry natural-origin index claims calculated under ISO 16128 and certifications from organisations such as COSMOS. Biosurfactants match this demand closely: sophorolipids and rhamnolipids are mild to skin and eyes, surfactin is highly surface-active at very low concentrations, and several biosurfactants offer additional skin-care benefits such as barrier support, moisturisation or antimicrobial activity. Premium positioning means personal care brands can absorb higher ingredient costs than mass-market detergent brands, making the application an attractive entry market for new producers. Strong growth in the beauty markets of China, South Korea, India and Southeast Asia, alongside established demand in France, the United States and Japan, supports continued expansion through 2032.
Growth of Biological Crop Inputs
Agriculture, valued at USD 220.47 Million in 2025 and growing at a CAGR of 5.03%, benefits from the rapid growth of the agricultural biologicals sector. Farmers and food retailers are seeking to reduce chemical residues, manage pesticide resistance and meet sustainability standards, while regulators in the European Union and elsewhere have withdrawn approvals for a number of synthetic active substances and co-formulants. Biosurfactants are used as adjuvants to improve the wetting and spreading of spray solutions, and certain molecules have direct biological activity: rhamnolipids have been registered as biofungicide actives in the United States, and Bacillus lipopeptides contribute to the efficacy of many microbial fungicides. Export-oriented horticulture in Latin America, Spain and Asia, and government support for sustainable agriculture, reinforce this driver.
Low-Cost and Waste-Derived Feedstocks
Feedstock is a major component of biosurfactant production cost. The use of by-product and waste streams, such as used cooking oil, crude glycerol from biodiesel production, molasses, food processing residues and lignocellulosic sugars, offers a route to lower costs and stronger circularity credentials. Producers that integrate with agro-industrial and food processing operations can secure low-cost inputs and differentiate their products on life-cycle performance.
Strain Engineering and New Biosurfactant Molecules
Advances in synthetic biology, metabolic engineering and fermentation process intensification are raising titres and enabling the production of rhamnolipids in non-pathogenic hosts and of tailored glycolipid and lipopeptide structures with specific properties. These developments can reduce costs and open applications that require particular performance attributes, such as low-foaming industrial cleaners, specialised emulsifiers for food and pharmaceuticals, or targeted antimicrobial activity.
Expansion in Emerging Markets
Asia Pacific, Latin America and the Middle East & Africa combine fast-growing consumer markets with abundant fermentation feedstocks and supportive industrial policies. Asia Pacific is projected to add USD 182.41 Million between 2025 and 2032, and the Middle East & Africa and Latin America are the two fastest-growing regions. Establishing production, application laboratories and distribution partnerships in these regions provides an opportunity to capture growth close to demand and to reduce logistics costs.
High Production Costs Relative to Conventional Surfactants
Biosurfactants remain significantly more expensive than petrochemical surfactants such as linear alkylbenzene sulfonate and alcohol ethoxylates, and than chemically synthesised bio-based surfactants such as alkyl polyglucosides. Fermentation processes have lower volumetric productivity than chemical synthesis, and downstream recovery and purification can represent a large share of production cost. This cost premium limits use in price-sensitive mass-market detergents and in large-volume industrial applications, and it means that adoption often depends on brand owners' willingness to pay for sustainability attributes.
Limited Production Capacity and Scale-Up Risk
Global biosurfactant production capacity is small relative to the overall surfactant market and is concentrated among a limited number of suppliers. Scaling fermentation from pilot to industrial volumes involves technical risks, including foaming during fermentation, product inhibition and batch-to-batch consistency, and requires significant capital. Large brand owners require security of supply and multiple qualified sources before committing major product lines, so limited capacity can slow adoption even where demand exists.
Formulation and Qualification Barriers
Replacing established surfactants requires extensive reformulation and testing for stability, performance, compatibility, colour and odour. Some biosurfactants have different foaming or viscosity behaviour from the surfactants they replace, and crude grades may carry residual fermentation by-products. Qualification cycles at major brand owners can take a year or more, and regulatory registration of new substances in some jurisdictions adds time and cost.
Strategic Partnerships Across the Value Chain
Biotechnology start-ups, chemical majors and consumer goods companies are increasingly working together through supply agreements, joint development and equity investments. Specialists contribute strain and process know-how, chemical companies contribute scale-up, regulatory and distribution capabilities, and brand owners provide demand commitments. This trend is accelerating commercialisation and is expected to continue through the forecast period.
Growth of Certified Bio-Based and Natural-Origin Claims
Product claims are becoming more standardised. European standards for bio-based surfactants, ISO 16128 natural-origin calculations for cosmetics, the USDA Certified Biobased Product label and eco-labels provide frameworks for communicating renewable content. As claims are scrutinised more closely under green-claims rules, biosurfactants with verifiable fully bio-based content gain an advantage.
Competition from Other Bio-Based Surfactants
Biosurfactants compete not only with petrochemical surfactants but also with chemically synthesised bio-based surfactants such as alkyl polyglucosides, sugar esters, amino acid surfactants and surfactants made from renewable ethylene. These alternatives are often cheaper and available at larger scale, so biosurfactant producers must demonstrate superior performance, mildness or life-cycle benefits to justify their premium.
Scale-Up and Supply Security
A key challenge for the industry is to demonstrate reliable, consistent supply at industrial scale. Delays in commissioning, technical setbacks and the capital intensity of fermentation plants can erode the confidence of large buyers. Suppliers that can offer multi-site production, robust quality systems and long-term pricing will be best placed to win large-volume contracts.
The biosurfactant value chain extends from renewable feedstocks through fermentation and purification to distribution and end-use formulation. Value addition is concentrated in the manufacturing stage, where proprietary microbial strains, fermentation know-how and downstream processing determine cost and product quality.
Raw materials and inputs: The main carbon sources are sugars (glucose, sucrose and molasses from corn, wheat and sugarcane), vegetable oils and fatty acids (rapeseed, sunflower, palm and used cooking oil) and glycerol. Nutrients, process water and energy are additional inputs. Feedstock choice influences cost, yield and sustainability credentials.
Manufacturing: Producers develop and maintain proprietary yeast and bacterial strains, run batch or fed-batch fermentations, and recover the product through separation, extraction, crystallisation, precipitation or membrane processes. Products are standardised as concentrates, solutions or powders. Some companies operate their own plants, while others use contract fermentation partners.
Distribution and channels: Large volumes are supplied directly to brand owners under long-term agreements. Specialty chemical distributors and ingredient houses serve smaller formulators, cosmetic brands and regional markets, often providing technical support and formulation guidance.
End users: Household and institutional cleaning product manufacturers, personal care and cosmetics companies, agrochemical and biologicals formulators, oilfield service companies, remediation contractors and other industrial users incorporate biosurfactants into finished products.
Biosurfactants are regulated as chemical substances and, depending on use, as detergent ingredients, cosmetic ingredients or agricultural products. Key regulations and standards in major regions are summarised below.
Europe
Europe has the most developed regulatory framework for surfactants and bio-based products. The new Regulation (EU) 2026/405 on detergents and surfactants will apply from September 2029, after a transition period, and is expected to raise the bar on biodegradability while explicitly addressing microbial ingredients.
North America
In the United States, market access is shaped by federal chemical, pesticide and cosmetic legislation, while demand is supported by federal biobased procurement rules and voluntary eco-labels.
Asia Pacific
In Asia Pacific, new chemical substance and cosmetic ingredient registration rules govern market entry, while national bioeconomy policies in Japan and India support domestic bio-manufacturing.
Jan 2022: Evonik; Expansion; Announced investment in the first industrial-scale rhamnolipid plant at Slovenská Ľupča, Slovakia, strengthening its partnership with Unilever.
Feb 2022: Locus FS; Partnership; Signed an exclusive agreement with Dow to market Locus sophorolipids to the global personal care industry.
Mar 2022: Holiferm / Sasol; Partnership; Formed a strategic partnership under which Sasol takes most of Holiferm's sophorolipid output and supports R&D.
Jun 2022: Evonik; Expansion; Started construction of the rhamnolipid plant in Slovakia.
Aug 2022: AGAE Technologies; Expansion; Announced dedicated rhamnolipid fermentation and purification pilot plants in North America.
Sep 2022: Locus FS; Regulatory / Market Entry; Obtained REACH registrations for its sophorolipid range and entered the EU market.
Jan 2023: Sasol / Holiferm; Partnership; Extended their collaboration to the development of rhamnolipids and mannosylerythritol lipids.
Feb 2023: Holiferm; Expansion; Opened its first commercial sophorolipid plant at Wallasey, U.K., with initial capacity of about 1,100 tonnes per year.
Apr 2023: Locus FS; Partnership; Entered an exclusive collaboration with Veolia Water Technologies & Solutions on sophorolipid-based water treatment additives.
2023: Locus FS; Investment; Secured a USD 117 million IP-backed loan to expand biosurfactant manufacturing capacity.
Oct 2023: Sasol; Product Launch; Launched CARINEX SL and LIVINEX SL sophorolipids for personal care and home care.
Dec 2023: Holiferm; Investment; Raised GBP 18.5 million to expand sophorolipid capacity at Wallasey.
Jan 2024: Evonik; Expansion; Manufactured the first rhamnolipid product at its Slovakia site.
May 2024: Evonik; Expansion; Inaugurated the industrial-scale rhamnolipid plant at Slovenská Ľupča.
Oct 2024: Allied Carbon Solutions; Investment; Raised JPY 550 million in a Series C round to expand sophorolipid production and overseas sales.
Oct 2024: Locus FS; Regulatory; Full glycolipid product line listed on the U.S. TSCA Inventory.
Feb 2025: AGAE Technologies; Expansion; Began industrial rhamnolipid production at a full-scale manufacturing plant in Asia with capacity above 1,000 tonnes per year.
May 2025: Holiferm; Partnership; Appointed Creatreats as distributor of HoliSurf biosurfactants in Spain and Portugal.
Jun 2025: Allied Carbon Solutions; Partnership; Selected by UNIDO for a feasibility study on producing sophorolipids from Ukrainian sunflower oil.
Sep 2025: Saraya; Product Launch; Launched Happy Elephant Foam Multi Cleaner containing SOFORO sophorolipid nationwide in Japan.
Dec 2025: Stepan; Divestment; Completed the sale of its Lake Providence, Louisiana, manufacturing assets.
Dec 2025: Locus FS; Investment; Raised a USD 20 million convertible note to support growth.
Mar 2026: Allied Carbon Solutions; Product Launch; Launched a sophorolipid-based biostimulant for heat and drought stress.
Mar 2026: Saraya; Product Launch; Introduced a paper-carton refill of Happy Elephant liquid laundry detergent containing SOFORO.
Jun 2026: Evonik; Partnership; Partnered with the University of Guanajuato, Mexico, to develop lower-toxicity mining chemicals using rhamnolipids.
Sep 2026: Locus FS; Acquisition; Acquired a facility in Midland, Texas, tripling its Permian blending capacity.
Sep 2026: Holiferm; Merger; Announced a strategic combination with cleaning products manufacturer Organica.
Political
National and regional bioeconomy strategies, including those of the European Union, the United States, China and India, prioritise bio-manufacturing and provide funding for scale-up.
Public procurement preferences for biobased products, such as the USDA BioPreferred Program, create institutional demand.
Trade policy and tariffs on chemical imports affect the delivered cost of biosurfactants in import-dependent regions.
Economic
The cost premium of biosurfactants over conventional surfactants is the main economic barrier to adoption in price-sensitive segments.
Feedstock and energy prices directly affect production costs, while crude oil prices influence the cost of competing petrochemical surfactants.
Rising disposable incomes in emerging economies support demand for premium home and personal care products.
Social
Consumer preference for natural, gentle and environmentally responsible products is strong, particularly among younger consumers.
Growing awareness of water pollution and the environmental fate of chemicals supports demand for readily biodegradable ingredients.
Demand for residue-free food production encourages the use of biological crop inputs.
Technological
Strain engineering, synthetic biology and process intensification are raising titres and lowering costs.
Improved downstream processing, including membrane separation and continuous recovery, reduces purification costs.
New molecules and grades are being developed for specific performance requirements across applications.
Environmental
Biosurfactants offer renewable carbon content, ready biodegradability and low aquatic toxicity, supporting corporate climate and environmental targets.
Life-cycle performance depends on feedstock choice, and land-use concerns associated with some vegetable oils, such as palm oil, require responsible sourcing.
Biosurfactants are used in oil spill response and soil remediation, linking the market to environmental clean-up activity.
Legal
Chemical registration requirements, such as EU REACH, U.S. TSCA and China's new chemical substance rules, impose time and cost on new molecules.
Cosmetic, detergent and pesticide regulations govern the use of biosurfactants in specific products.
Rules on environmental and green claims require substantiation of bio-based and sustainability statements.
Profiles of 31 companies operating in the Bio-Based Surfactants Market market, including revenue, employee count, and market positioning where available.
Showing 31 of 31 companies
Kaneka is a mid-cap Japanese diversified chemical company. Over the past decade it has been reshaping itself from a commodity-heavy vinyls, foams and fibres producer into what management calls a "Life Focus" solutions company. FY2026 sales were a record ¥811.6bn. They are spread across four reportable units: - Material Solutions (PVC, modifiers, MS polymer, the biodegradable polymer Green Planet™) - Quality of Life Solutions (polyimide films, PV, foams, modacrylic fibres) - Health Care Solutions (blood-purification devices, catheters, neuro-coils, pharma CDMO) - Nutrition Solutions (Kaneka Ubiquinol™, probiotics, margarine/yeast/dairy) Kaneka is a global leader in several niche chemistries: MBS/acrylic impact modifiers, silyl-terminated polyether (MS Polymer™), reduced coenzyme Q10, and modacrylic hair fibre. Profitability is structurally low, with a 4.1% operating margin in FY2026 and a 6.4% ROE. The stock traded at a P/B of about 0.7x in September 2026. Management's 2026 plan targets ¥68bn operating income and 10% ROE by FY2029 (Kaneka "FY2028"). It relies on Medical, E&I and supplement growth, plus aggressive capital-efficiency measures. --- ### What Kaneka does Kaneka makes and sells a broad portfolio of chemical, materials, medical, pharmaceutical and food products. It organises them into ten "Solutions Vehicles" (SVs), grouped into four "Solutions Units" (SUs), which are the reportable segments. Per the FY2026 Tanshin segment note, each SU sets a single global strategy and runs Japanese and overseas subsidiaries as one business. **Company's own description (paraphrased from the FY2026 Tanshin segment note):** **Material SU:** supplies high-performance materials for social infrastructure and lighter, more fuel-efficient mobility, plus advanced materials such as biodegradable polymers that serve environmental goals. **Quality of Life SU:** supplies materials and services for energy saving and smart housing and infrastructure, and serves the IoT/AI information economy. **Health Care SU:** combines devices and pharmaceuticals for medicine, health and nursing care. It is building businesses in biopharmaceuticals and regenerative/cell medicine. **Nutrition SU:** supplies distinctive food materials and supplements for diverse diets and health. It also supports agriculture, livestock and fisheries production. **Corporate purpose framing (Three-Year Initiatives 2026).** The corporate purpose is "KANEKA thinks 'Wellness First'". Its supporting pillars are Life Focus Management, Human-Driven Management, R2B+P ("Research to Business + Production") and "Think Global, Act Local". Management defines "life science" broadly. It covers biomanufacturing (Green Planet™, genome editing, fermentation), biopharma, regenerative medicine, supplements, organic dairy, PV and medical devices — all presented as serving "life on Earth". ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales (B2B materials, devices, ingredients, foods). Contract manufacturing (CDMO) revenue sits within Pharma. Kaneka does not disclose any subscription or licensing revenue line; licensing income is not separately reported | | Product vs. service mix | Not disclosed. Kaneka's independent assessment is that product sales are more than 95% of revenue; services are limited to construction-method/PV installation-related services in QOL and CDMO services in Pharma | | Value-chain position | Mid-stream: intermediates, specialty polymers and additives. Downstream: finished medical devices, PV modules, consumer-facing supplements and dairy products. Upstream exposure through chlor-alkali/PVC (naphtha, salt, power) | | Customer types | Industrial compounders and converters (PVC, adhesives/sealants, automotive), electronics makers (FPC/smartphone, TV), housing builders, hospitals and distributors (medical devices), pharma companies (CDMO/API), supplement brands, food manufacturers and bakeries, agricultural users | | End-markets | Construction and housing; automotive and mobility; electronics/ICT (smartphones, AI-related high-frequency); renewable energy; healthcare (cardiology, nephrology/apheresis, neurovascular, GI endoscopy); pharma; dietary supplements; bakery and food; agriculture | | Geographic mix (FY2026) | Japan 55.2%, Asia 20.1%, Europe 10.3%, North America 9.2%, Other 5.2% (FY2026 Tanshin) | ### "Leading-edge" vs "Foundation" portfolio lens Management splits the portfolio into two groups (Three-Year Initiatives 2026): **Leading-edge businesses:** Modified Silicone polymers (MS), E&I Technology, PV & Energy management, Medical, Pharma, and Supplemental Nutrition. **Foundation businesses:** Vinyls & Chlor-Alkali, Modifiers (MOD), Foam & Residential Techs, Performance Fibers, and Foods & Agris. Leading-edge businesses supplied 53% of operating income in FY2026, up from 48% in FY2025. The target is 56% in FY2027 and 62% by FY2029. The 2026 plan also puts Green Planet™ and genome editing in the life-science growth pool. ### Independent characterisation Kaneka is best understood as a portfolio of ten mid-sized niche businesses sitting on a cyclical commodity base. About 40% of revenue (Material SU) is exposed to Asian PVC pricing and Western construction demand. That base has driven most of the earnings volatility seen in FY2026. The value-creation engine lies elsewhere: **Medical devices:** the Health Care SU earned a 17.9% segment margin in FY2026. **E&I polyimide films:** these benefit from AI-driven high-frequency demand. **Global ubiquinol franchise:** The central investment question is whether these businesses can scale fast enough to lift group margins from about 4% toward the 7.3% FY2029 target. A secondary question is whether that can happen before the corporate cost burden absorbs the gains: unallocated corporate expenses (mainly basic R&D) were ¥39.1bn in FY2026, larger than total group operating income.
Company Headquarters: Illinois, US Founded: 1932 Workforce: ~2,250 Company Working: Stepan Company (Stepan) is engaged in the manufacturing and sale of specialty and intermediate chemicals. It operates through the segments, namely surfactants, polymers, and specialty products. Surfactants segment offers oilfield biocides along with a wide range of surfactant chemicals such as anionic, cationic, nonionic, and amphoteric surfactants. The polymers segment produces polyester polyols and phthalic anhydride. The specialty products are chemicals used in food, flavoring, nutritional supplement, and pharmaceutical applications.
Sasol is South Africa's largest integrated energy and chemicals producer and the world's leading commercial operator of Fischer-Tropsch coal-to-liquids and gas-to-liquids technology. Its Southern African value chain begins with captive coal mines and Mozambican natural gas. These feed the Secunda synthetic fuels and chemicals complex and the Sasolburg chemicals operations. The chain extends through the Natref crude refinery to wholesale, commercial and retail fuel channels, and it anchors a domestic polymers, solvents and specialty chemicals business. International Chemicals (the Lake Charles complex in the United States plus sites in Germany, Italy and China) adds alcohols, surfactants, alumina, waxes and olefins. Since 2024 CEO Simon Baloyi has run a "reset". Its main elements are: restoring Secunda volumes and coal quality, cutting cost and capex, closing loss-making international units, and deleveraging towards US$3bn of net debt before dividends resume. FY2026 delivered adjusted EBITDA up 17% to R60.7bn and net debt of US$3.3bn. The equity nevertheless remains a geared exposure to oil, the rand and chemical cycles, overlaid by heavy carbon-transition risk. --- ### Company self-description In its FY2026 materials Sasol describes itself as a global energy and chemicals company. It says it applies its knowledge and technology inside large, world-scale plants, and that it sources, produces and markets a broad range of products to create value for stakeholders [AIA26]. Its product overview lists: diesel, petrol, naphtha, jet fuel, LPG, olefins, alcohols, polymers, solvents, surfactants, co-monomers, ammonia, methanol, crude tar acids, sulphur, illuminating paraffin, bitumen and fuel oil, plus further derivatives [R26 web page]. ### Independent characterisation Sasol is two businesses joined by a balance sheet. 1. **Southern Africa Energy and Chemicals (SA E&C).** This is a vertically integrated, coal- and gas-based Fischer-Tropsch value chain. - **Inputs:** 28.4 mm tons of saleable coal (FY2026) and 114.0 bscf of Mozambican natural gas. - **Conversion:** the Secunda Operations (SO) complex produced 7.26 mm tons in FY2026, of which fuels were 3.63 mm t and chemicals 3.00 mm t. Natref, Sasol's 63.64%-owned crude refinery, produced 25.8 mm bbl in FY2026. - **Sales:** 57.5 mm bbl of liquid fuels through three channels (Mobility/retail 10.5, Commercial 28.0, Wholesale 19.0 mm bbl), and 3,542 kt of Chemicals Africa external sales. - In FY2026 the segment generated R189.9bn of external turnover (70% of group) and R46.8bn of adjusted EBITDA (77% of group) [AIA26]. 2. **International Chemicals (IC).** This comprises Chemicals America (the Lake Charles, Louisiana complex: ethane cracker, Ziegler alcohols, alumina, ethylene oxide/glycol, tetramerisation, co-monomers) and Chemicals Eurasia (Germany, Italy, China: essential care chemicals, alcohols, linear alkylbenzene, paraffins, high-purity alumina). IC generated R82.2bn of external turnover (30%) and R10.2bn of adjusted EBITDA (US$604m; 12% margin) in FY2026 [AIA26]. ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue type | Almost entirely product sales (fuels, gas, chemicals). Minor other income comes from technology licence fees, rental income (including Richards Bay Coal Terminal capacity leasing), emission grants and insurance proceeds. No material subscription revenue | [AIA26] "Other income" note | | Product vs service vs licensing mix | Product ≈ 98–99%+. Licensing and services are not separately disclosed as revenue; they sit within other income (R4.1bn total other income in FY2026, all types) | [AIA26] | | Pricing | SA fuels are priced off the regulated Basic Fuel Price (import-parity) formula. SA piped gas is priced under NERSA maximum-gas-price regulation. Chemicals follow global commodity benchmarks (Sasol says it is not a price-setter for most of its chemicals portfolio) | [AIA26] key sensitivities; [20F26] | | Value-chain position | Upstream (coal mining, gas production) → midstream (FT synthesis, gasification, refining, cracking) → downstream (fuel retail, chemical derivatives) | [AIA26] | | Customer types | Fuel retailers and franchisees; commercial and industrial fuel buyers (mining, agriculture, transport, aviation including O.R. Tambo International Airport jet fuel supply); oil-company wholesale customers; industrial gas users; chemical converters and formulators (packaging, detergents, personal care, coatings, pharmaceuticals, catalysts, explosives) | [AIA26]; [NEWS] | | End-markets | Transport fuels and aviation; mining and explosives; agriculture (fertilisers); packaging and plastics (polyethylene, polypropylene, PVC); home and personal care (surfactants, alcohols); coatings, inks and adhesives (solvents); catalysts, ceramics and battery/advanced materials (alumina); energy and power | [20F26]; company product catalogue | ### Key FY2026 operating scale [AIA26] | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Saleable coal production (mm t) | 30.2 | 28.2 | 28.4 | | Mozambique natural gas production (bscf) | 120.8 | 122.2 | 114.0 | | Secunda Operations production (kt) | 6990 | 6721 | 7260 | | Natref production (mm bbl) | 17.8 | 14.7 | 25.8 | | ORYX GTL production, Sasol share basis (mm bbl) | 2.9 | 5.0 | 3.0 | | Liquid fuel sales (mm bbl) | 51.7 | 50.9 | 57.5 | | Chemicals Africa external sales (kt) | 3515 | 3375 | 3542 | | Chemicals America external sales (kt) | 1764 | 1592 | 1904 | | Chemicals Eurasia external sales (kt) | 1026 | 990 | 942 |
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
3 interactive charts drawn from the Bio-Based Surfactants Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Bio-Based Surfactants Market By Application
Global Bio-Based Surfactants Market By Product Type
Global Bio-Based Surfactants Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
